CVI Holdings’s Viridian Therapeutics VRDN Stock Holding History

CVI Holdings’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-6,147	Closed	-$646K	–	61
2018 Q1	$646K	Buy	+6,147	New	+$668K	0.88%	21

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CVI Holdings's VRDN Position: Q2 2018 in Review

CVI Holdings sold out of Viridian Therapeutics (VRDN) in Q2 2018, closing a stake of 6,147 shares — an estimated $646K sold.

CVI Holdings first reported a position in VRDN in Q1 2018 and held it in 1 quarter. The position peaked at $646K in Q1 2018. 59 funds tracked by Wall St. Rank hold VRDN as of Q2 2018.

CVI Holdings reported no remaining Viridian Therapeutics position as of Q2 2018 after selling out during the quarter.
CVI Holdings sold 6,147 Viridian Therapeutics shares in Q2 2018, an estimated $646K.
CVI Holdings first reported a position in Viridian Therapeutics in Q1 2018 and held it in 1 quarter.
CVI Holdings's Viridian Therapeutics position peaked at $646K in Q1 2018.
59 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2018.

Based on CVI Holdings's 13F filing for Q2 2018, filed 14 Aug 2018.